Malignant carotid body tumors: What we know, what we do, and what we need to achieve. A systematic review of the literature

Author:

Piazza Cesare12,Lancini Davide1,Tomasoni Michele1,Zafereo Mark3,Poorten Vincent Vander45ORCID,Hanna Ehab3,Mäkitie Antti A.6ORCID,Fernandez‐Alvarez Veronica7,Kowalski Luiz P.8,Chiesa‐Estomba Carlos9ORCID,Ferlito Alfio10

Affiliation:

1. Unit of Otorhinolaryngology – Head and Neck Surgery ASST Spedali Civili of Brescia Brescia Italy

2. Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health University of Brescia, School of Medicine Brescia Italy

3. Department of Head and Neck Surgery MD Anderson Cancer Center Houston Texas USA

4. Otorhinolaryngology – Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven Leuven Belgium

5. Department of Oncology, Section Head and Neck Oncology KU Leuven Leuven Belgium

6. Department of Otorhinolaryngology – Head and Neck Surgery, Research Program in Systems Oncology University of Helsinki and HUS Helsinki University Hospital Helsinki Finland

7. Department of Vascular and Endovascular Surgery Hospital Universitario de Torrecardenas Almeria Spain

8. Department of Head and Neck Surgery University of Sao Paulo Medical School and Department of Head and Neck Surgery and Otorhinolaryngology, AC Camargo Cancer Center Sao Paulo Brazil

9. Department of Otorhinolaryngology – Head and Neck Surgery Donostia University Hospital, Deusto University – School of Medicine, BioGuipuzcoa Research Institute San Sebastian Spain

10. Coordinator of the International Head and Neck Scientific Group Padua Italy

Abstract

AbstractMalignant carotid body tumors (MCBT) are rare and diagnosed after detection of nodal or distant metastases. This systematic review (SR) focuses on MCBT initially approached by surgery. Preferred Reporting Items for SR and Meta‐Analysis (MA) guided the articles search from 2000 to 2023 on PubMed, Scopus, and Web of Science. Among 3548 papers, 132 (337 patients) were considered for SR; of these, 20 (158 patients) for MA. Malignancy rate was 7.3%, succinate dehydrogenase (SDH) mutation 17%, age at diagnosis between 4th and 6th decades, with a higher prevalence of females. MCBTs were mostly Shamblin III, with nodal and distant metastasis in 79.7% and 44.7%, respectively. Malignancy should be suspected if CBT >4 cm, Shamblin III, painful or otherwise symptomatic, at the extremes of age, bilateral, with multifocal disease, and SDHx mutations. Levels II–III clearance should be performed to exclude nodal metastases and adjuvant treatments considered on a case‐by‐case basis.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3